Grant: Engage Grants Program
Université de Sherbrooke
$25,000.00
Characterization of new therapeutic neurotensin derivatives with increased brain penetration and potential analgesic efficacy
FY 2011-12
Summary
The tridecapeptide neurotensin (NT), inducing antinociception in the brain through interaction with two
identified receptors subtypes, NTS1 and NTS2, presents great potential for the development of a new class of
analgesics. However, because NT penetrates only poorly through the blood-brain barrier (BBB), its potential as
a therapeutic agent is limited to spinal injections, thus with weak clinical outcomes. Angiochem is a
pharmaceutical group focused on technologies to improve the BBB penetration of centrally active compounds.
Our goal is to initiate collaboration with Angiochem to investigate the brain uptake and analgesic effects of a
new chemical entity formed by the conjugation of NT to Angiopep-2, a 19-amino-acid peptide that crosses the
BBB. Preliminary results of in-situ brain perfusions in mice demonstrated that the Angiopep-2-NT conjugate,
ANG2002, efficiently penetrated the blood-brain barrier with a transport rate 10-fold higher than that of
unconjugated NT. Through our collaboration, we intend to determine, by in vivo studies, if the systemically
administered ANG2002 induces antinociceptive effects consistent with those of centrally administered NT in a
variety of acute, inflammatory, and neuropathic pain models. Our expertise in pain neurophysiology will allow
determining the potential of Angiochem's NT derivatives to address the reality of intractable chronic pain.
Program
Engage Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
411987-2010
Name nom
Sarret, Philippe
Department département
Physiologie et biophysique
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Characterization of new therapeutic neurotensin derivatives with increased brain penetration and potential analgesic efficacy
Keyword
NSERC
Application summary
The tridecapeptide neurotensin (NT), inducing antinociception in the brain through interaction with two
identified receptors subtypes, NTS1 and NTS2, presents great potential for the development of a new class of
analgesics. However, because NT penetrates only poorly through the blood-brain barrier (BBB), its potential as
a therapeutic agent is limited to spinal injections, thus with weak clinical outcomes. Angiochem is a
pharmaceutical group focused on technologies to improve the BBB penetration of centrally active compounds.
Our goal is to initiate collaboration with Angiochem to investigate the brain uptake and analgesic effects of a
new chemical entity formed by the conjugation of NT to Angiopep-2, a 19-amino-acid peptide that crosses the
BBB. Preliminary results of in-situ brain perfusions in mice demonstrated that the Angiopep-2-NT conjugate,
ANG2002, efficiently penetrated the blood-brain barrier with a transport rate 10-fold higher than that of
unconjugated NT. Through our collaboration, we intend to determine, by in vivo studies, if the systemically
administered ANG2002 induces antinociceptive effects consistent with those of centrally administered NT in a
variety of acute, inflammatory, and neuropathic pain models. Our expertise in pain neurophysiology will allow
determining the potential of Angiochem's NT derivatives to address the reality of intractable chronic pain.